Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · September 23, 2023

Efficacy and Safety of Dupilumab Up to 52 Weeks in Adults and Adolescents With Eosinophilic Oesophagitis

The Lancet Gastroenterology & Hepatology


Additional Info

The Lancet Gastroenterology & Hepatology
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Gastroenterol Hepatol 2023 Aug 31;[EPub Ahead of Print], ME Rothenberg, ES Dellon, MH Collins, I Hirano, M Chehade, AJ Bredenoord, AJ Lucendo, JM Spergel, X Sun, JD Hamilton, E Mortensen, E Laws, J Maloney, LP Mannent, E McCann, X Liu, L Glotfelty, A Shabbir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading